SOURCE: SK3 Group, Inc.

March 24, 2014 09:30 ET

SK3 Group's Wholesale Managed Collective Portfolio Announces New Distributor in San Francisco Bay Area Expanding Company Product Reach

LOS ANGELES, CA--(Marketwired - Mar 24, 2014) - SK3 Group's (OTC Pink: SKTO) (PINKSHEETS: SKTO) Medical Greens subsidiary is pleased to announce that it now has an additional new distributor in the San Francisco Bay Area in California for its wholesale managed collective portfolio. This step increases the reach of its wholesale managed collective portfolio into additional medical cannabis dispensaries and delivery services for its various product lines including: Dharmanol, Canna-Loz Organic Oil, T-Hydro-Can, Yak Capsules, Yeti Honeybud Oilers, Organakoil, Greenie Whole Plant Cookies, Haute Chocolate Instant Drink Mix, and Mocha-juana Instant Drink Mix. This also opens the way for additional expansion of the Pharmajanes.com delivery service.

The total population of the San Francisco Bay Area is over 7.1 million people, making it the second most populous urban area in California after the Greater Los Angeles area, and the fifth largest in the United States.

The Bay Area is where some of the most regulated and politically supportive cities for medical marijuana in California are located, such as San Francisco, Berkeley, and Oakland.

"This is another important addition to our distribution network for our licensed products," said Artemus Mayor, President of SK3 Group. "San Francisco was home to the first public medical cannabis dispensary in the United States, which paved the way for expansion of medical marijuana to where we are today. We are continuing to broaden our distribution network into key markets to facilitate getting medicine to more patients who need our licensed medical cannabis products as we build our brand."

About SKTO
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information